<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some new guidelines have been published by European (2010) and American (2011) Societies of Cardiology regarding to the management of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, the most frequent <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> affecting from 1 to 2% of the global population </plain></SENT>
<SENT sid="1" pm="."><plain>In this article we summarize and analyse the new aspects of these guidelines in which the different types of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> are redefined, as well as new criterias for the indication of oral anticoagulation and <z:mp ids='MP_0001914'>bleeding</z:mp> risk </plain></SENT>
<SENT sid="2" pm="."><plain>New antiarrhythmic and <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> molecules also appear in these guidelines, and there is growing evidence for the use of catheter ablation </plain></SENT>
</text></document>